Epigenetic silencing of miR-145-5p contributes to brain metastasis

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35183-35201

  Donzelli, Sara ^a   Mori, Federica ^a   Bellissimo, Teresa ^a   Sacconi, Andrea ^a   Casini, Beatrice ^a   Frixa, Tania ^a   Roscilli, Giuseppe ^b   Aurisicchio, Luigi ^b   Facciolo, Francesco ^a   Pompili, Alfredo ^a   Carosi, Maria Antonia ^a   Pescarmona, Edoardo ^a   Segatto, Oreste ^a   Pond, Greg ^c   Muti, Paola ^c   Telera, Stefano ^a   Strano, Sabrina ^a,c   Yarden, Yosef ^d   Blandino, Giovanni ^a,c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Takis srl   (Italy)

^c MCMASTER UNIVERSITY   (Canada)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Brain metastases; Epigenetic modifications; Lung cancer; Migration; Mir 145 5p

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA 145; MICRORNA 145 5P; MUCIN 1; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TUMOR PROTEIN; TUMOR PROTEIN D52; UNCLASSIFIED DRUG; MICRORNA; MIRN145 MICRORNA, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; CANCER CELL; CELL MIGRATION; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENETIC DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIMARY TUMOR; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN TARGETING; ANIMAL; BIOSYNTHESIS; BRAIN TUMOR; CELL MOTION; CPG ISLAND; GENETIC EPIGENESIS; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE SILENCING; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICRORNAS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

EID: 84946893445     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5930     Document Type: Article

References (47)

1. Nayak L, Lee EQ and Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012; 14:48-54.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58:71-96.
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P and Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22:2865-2872.
4. Schouten LJ, Rutten J, Huveneers HA and Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002; 94:2698-2705.
5. Eichler AF and Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007; 12:884-898.
6. Lombardi G, Di Stefano AL, Farina P, Zagonel V and Tabouret E. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat Rev. 2014; 40:951-959.
7. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D and Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011; 8:344-356.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
9. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101:2999-3004.
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR. MicroRNA expression profiles classify human cancers. Nature. 2005; 435:834-838.
11. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10:704-714.
12. Lopez-Serra P and Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene. 2012; 31:1609-1622.
13. Melo SA and Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res. 2012; 18:4234-4239.
14. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004; 101:11755-11760.
15. Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, et al. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis. 2012; 3:e423.
16. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, et al. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med. 2012; 4:1214-1229.
17. Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, Muti P, Strano S, Spriano G, Fontemaggi G and Blandino G. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol. 2013; 24:3082-3088.
18. Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, Carosi MA, Blandino R, Panebianco V, Facciolo F, Visca P, Volinia S, et al. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene. 2014; 33:5319-5331.
19. Muti P, Sacconi A, Hossain A, Donzelli S, Ben Moshe NB, Ganci F, Sieri S, Krogh V, Berrino F, Biagioni F, Strano S, Beyene J, Yarden Y and Blandino G. Downregulation of microRNAs 145-3p and 145-5p Is a Long-term Predictor of Postmenopausal Breast Cancer Risk: The ORDET Prospective Study. Cancer Epidemiol Biomarkers Prev. 2014; 23:2471-2481.
20. Ganci F, Vico C, Korita E, Sacconi A, Gallo E, Mori F, Cambria A, Russo E, Anile M, Vitolo D, Pescarmona E, Blandino R, Facciolo F, Venuta F, Blandino G, Marino M, et al. MicroRNA expression profiling of thymic epithelial tumors. Lung Cancer. 2014; 85:197-204.
21. Lee HK, Bier A, Cazacu S, Finniss S, Xiang C, Twito H, Poisson LM, Mikkelsen T, Slavin S, Jacoby E, Yalon M, Toren A, Rempel SA and Brodie C. MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One. 2013; 8:e54652.
22. Hart M, Nolte E, Wach S, Szczyrba J, Taubert H, Rau TT, Hartmann A, Grasser FA and Wullich B. Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. Mol Cancer Res. 2014; 12:250-263.
23. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, Forte S, De Maria R and Ricci-Vitiani L. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013; 32:4806-4813.
24. Zhang J, Sun Q, Zhang Z, Ge S, Han ZG and Chen WT. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene. 2013; 32:61-69.
25. Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, Liu M, Gao X, Liu Y, Zhao C, Wang X, Wang N, Li J, Liu R, Zen K, Zhang CY, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 2014; 13:220.
26. Sachdeva M and Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res. 2010; 2:170-180.
27. Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C, Li H and Shi DB. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene. 2013; 32:491-501.
28. Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ, Jiang Y, Chen X, Qi Y, Zhang X, Wang X, Sun Q, Kung HF, Lin MC, Dress A, Wardle F, et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle. 2012; 11:2137-2145.
29. Dynoodt P, Speeckaert R, De Wever O, Chevolet I, Brochez L, Lambert J and Van Gele M. miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol. 2013; 42:1443-1451.
30. Yin R, Zhang S, Wu Y, Fan X, Jiang F, Zhang Z, Feng D, Guo X and Xu L. microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep. 2011; 25:1747-1754.
31. Cho WC, Chow AS and Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011; 8:125-131.
32. Sachdeva M and Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010; 70:378-387.
33. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K and Mo YY. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009; 106:3207-3212.
34. Bitler BG, Goverdhan A and Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci. 2010; 123:1716-1723.
35. Dweep H, Sticht C, Pandey P and Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform. 2011; 44:839-847.
36. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511:543-550.
37. Byrne JA, Frost S, Chen Y and Bright RK. Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumour Biol. 2014; 35:7369-7382.
38. Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa M, Naya Y, Ichikawa T and Seki N. Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett. 2014; 588:1973-1982.
39. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61-70.
40. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, Chen S, Lai Y, Du H, Chen G, Liu G, Tang Y, Huang S and Zou X. Identification of miRs-143 and-145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One. 2011; 6:e20341.
41. Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, Blandino G, et al. EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal. 2010; 3:ra43.
42. Dai X, Ge J, Wang X, Qian X, Zhang C and Li X. OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncol Rep. 2013; 29:155-160.
43. Horm TM and Schroeder JA. MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr. 2013; 7:187-198.
44. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J and Weinberg RA. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010; 12:247-256.
45. Andl CD, Mizushima T, Oyama K, Bowser M, Nakagawa H and Rustgi AK. EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. Am J Physiol Gastrointest Liver Physiol. 2004; 287:G1227-1237.
46. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011; 1:598-607.
47. Gyorffy B, Lanczky A and Szallasi Z. Implementing an online tool for genome-wide validation of survivalassociated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19:197-208.